APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

In Vivo Pharmacology Model

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global In Vivo Pharmacology Model Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 17416111033 May 2026199 pages

Choose your research edition.

Industry ResearchIn Vivo Pharmacology Model Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal In Vivo Pharmacology Model Industry Growth and Trends Forecast to 2032120 pages · $3,450 USDMarket StructureGlobal In Vivo Pharmacology Model Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal In Vivo Pharmacology Model Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal In Vivo Pharmacology Model Market Analysis and Forecast 2026-2032249 pages · $4,950 USD

Market perspective

The global In Vivo Pharmacology Model market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The US & Canada market for In Vivo Pharmacology Model is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for In Vivo Pharmacology Model is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for In Vivo Pharmacology Model is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for In Vivo Pharmacology Model is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of In Vivo Pharmacology Model include NuChem Sciences Inc, Eurofins Discovery, Oncodesign Services, Jubilant Biosys, Pharmaron, Melior Discovery, NUVISAN GmbH, Porsolt and Sygnature Discovery, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Includes

This report provides an overview of the global In Vivo Pharmacology Model market and its size, analyzing global market trends based on historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of In Vivo Pharmacology Model and revenue in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents In Vivo Pharmacology Model revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering revenue and growth rates—for 2021-2032, and evaluates and forecasts the In Vivo Pharmacology Model market size, projected growth trends, production technologies, key applications, and end-use industries.

In Vivo Pharmacology Model Segment by Company

NuChem Sciences Inc

Eurofins Discovery

Oncodesign Services

Jubilant Biosys

Pharmaron

Melior Discovery

NUVISAN GmbH

Porsolt

Sygnature Discovery

Aurigene Pharmaceutical Services Ltd

Reaction Biology

Addexbio

Paraza Pharma, Inc

Aragen Life Sciences Ltd

Dalriada

Biocytogen

Charles River Laboratories

Pharmacelsu

HitGen Inc

TCG Lifesciences

In Vivo Pharmacology Model Segment by Type

Inflammation Animal Models

Pain and Neuroscience Animal Models

Diabetes and Metabolic Disorders Animal Models

Oncology Animal Models

Others

In Vivo Pharmacology Model Segment by Application

Cardiovascular Diseases

Neurological Diseases

Autoimmune Diseases

Others

In Vivo Pharmacology Model Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global In Vivo Pharmacology Model market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of In Vivo Pharmacology Model and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of In Vivo Pharmacology Model.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. Revenue of In Vivo Pharmacology Model in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global In Vivo Pharmacology Model industry.

Chapter 3: Detailed analysis of In Vivo Pharmacology Model companies' competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, In Vivo Pharmacology Modelrevenue, gross margin, and recent development, etc.

Chapter 7: North America (US & Canada) by type, by application and by country, revenue for each segment.

Chapter 8: Europe by type, by application and by country, revenue for each segment.

Chapter 9: China by type, and by application, revenue for each segment.

Chapter 10: Asia (excluding China) by type, by application and by region, revenue for each segment.

Chapter 11: South America, Middle East & Africa by type, by application and by country, revenue for each segment.

Chapter 12: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global In Vivo Pharmacology Model Market Size Growth Rate by Type (US$ Million): 2021 VS 2025 VS 2032 Table 2. Key Players of Inflammation Animal Models Table 3. Key Players of Pain and Neuroscience Animal Models Table 4. Key Players of Diabetes and Metabolic Disorders Animal Models Table 3. Key Players of Oncology Animal Models Table 4. Key Players of Others Table 5. Global In Vivo Pharmacology Model Market Size Growth Rate by Application (US$ Million): 2021 VS 2025 VS 2032 Table 6. Key Players of Cardiovascular Diseases Table 7. Key Players of Neurological Diseases Table 8. Key Players of Autoimmune Diseases Table 9. Key Players of Others Table 10. Global In Vivo Pharmacology Model Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 11. Global In Vivo Pharmacology Model Market Size by Region (2021-2026) & (US$ Million) Table 12. Global In Vivo Pharmacology Model Market Share by Region (2021-2026) Table 13. Global In Vivo Pharmacology Model Market Size by Region (2027-2032) & (US$ Million) Table 14. Global In Vivo Pharmacology Model Market Share by Region (2027-2032) Table 15. In Vivo Pharmacology Model Industry Trends Table 16. In Vivo Pharmacology Model Industry Drivers Table 17. In Vivo Pharmacology Model Industry Opportunities and Challenges Table 18. In Vivo Pharmacology Model Industry Restraints Table 19. Global In Vivo Pharmacology Model Revenue by Company (US$ Million) & (2021-2026) Table 20. Global In Vivo Pharmacology Model Revenue Market Share by Company (2021-2026) Table 21. Global In Vivo Pharmacology Model Players Revenue Ranking, 2024 VS 2025 VS 2026 Table 22. Global In Vivo Pharmacology Model Key Company Head Office and Area Served Table 23. Global In Vivo Pharmacology Model Company, Product Type & Application Table 24. Global In Vivo Pharmacology Model Company Establishment Date Table 25. Global Company Market Concentration Ratio (CR5 and HHI) Table 26. Global In Vivo Pharmacology Model by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 27. Global In Vivo Pharmacology Model Market Size by Type 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global In Vivo Pharmacology Model Market Size by Type (2021-2026) & (US$ Million) Table 29. Global In Vivo Pharmacology Model Market Size by Type (2027-2032) & (US$ Million) Table 30. Global In Vivo Pharmacology Model Revenue Market Share by Type (2021-2026) Table 31. Global In Vivo Pharmacology Model Revenue Market Share by Type (2027-2032) Table 32. Global In Vivo Pharmacology Model Market Size by Application 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global In Vivo Pharmacology Model Market Size by Application (2021-2026) & (US$ Million) Table 34. Global In Vivo Pharmacology Model Market Size by Application (2027-2032) & (US$ Million) Table 35. Global In Vivo Pharmacology Model Revenue Market Share by Application (2021-2026) Table 36. Global In Vivo Pharmacology Model Revenue Market Share by Application (2027-2032) Table 37. NuChem Sciences Inc Company Information Table 38. NuChem Sciences Inc Business Overview Table 39. NuChem Sciences Inc In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 40. NuChem Sciences Inc In Vivo Pharmacology Model Product Portfolio Table 41. NuChem Sciences Inc Recent Development Table 42. Eurofins Discovery Company Information Table 43. Eurofins Discovery Business Overview Table 44. Eurofins Discovery In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 45. Eurofins Discovery In Vivo Pharmacology Model Product Portfolio Table 46. Eurofins Discovery Recent Development Table 47. Oncodesign Services Company Information Table 48. Oncodesign Services Business Overview Table 49. Oncodesign Services In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 50. Oncodesign Services In Vivo Pharmacology Model Product Portfolio Table 51. Oncodesign Services Recent Development Table 52. Jubilant Biosys Company Information Table 53. Jubilant Biosys Business Overview Table 54. Jubilant Biosys In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 55. Jubilant Biosys In Vivo Pharmacology Model Product Portfolio Table 56. Jubilant Biosys Recent Development Table 57. Pharmaron Company Information Table 58. Pharmaron Business Overview Table 59. Pharmaron In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 60. Pharmaron In Vivo Pharmacology Model Product Portfolio Table 61. Pharmaron Recent Development Table 62. Melior Discovery Company Information Table 63. Melior Discovery Business Overview Table 64. Melior Discovery In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 65. Melior Discovery In Vivo Pharmacology Model Product Portfolio Table 66. Melior Discovery Recent Development Table 67. NUVISAN GmbH Company Information Table 68. NUVISAN GmbH Business Overview Table 69. NUVISAN GmbH In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 70. NUVISAN GmbH In Vivo Pharmacology Model Product Portfolio Table 71. NUVISAN GmbH Recent Development Table 72. Porsolt Company Information Table 73. Porsolt Business Overview Table 74. Porsolt In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 75. Porsolt In Vivo Pharmacology Model Product Portfolio Table 76. Porsolt Recent Development Table 77. Sygnature Discovery Company Information Table 78. Sygnature Discovery Business Overview Table 79. Sygnature Discovery In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 80. Sygnature Discovery In Vivo Pharmacology Model Product Portfolio Table 81. Sygnature Discovery Recent Development Table 82. Aurigene Pharmaceutical Services Ltd Company Information Table 83. Aurigene Pharmaceutical Services Ltd Business Overview Table 84. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 85. Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Product Portfolio Table 86. Aurigene Pharmaceutical Services Ltd Recent Development Table 87. Reaction Biology Company Information Table 88. Reaction Biology Business Overview Table 89. Reaction Biology In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 90. Reaction Biology In Vivo Pharmacology Model Product Portfolio Table 91. Reaction Biology Recent Development Table 92. Addexbio Company Information Table 93. Addexbio Business Overview Table 94. Addexbio In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 95. Addexbio In Vivo Pharmacology Model Product Portfolio Table 96. Addexbio Recent Development Table 97. Paraza Pharma, Inc Company Information Table 98. Paraza Pharma, Inc Business Overview Table 99. Paraza Pharma, Inc In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 100. Paraza Pharma, Inc In Vivo Pharmacology Model Product Portfolio Table 101. Paraza Pharma, Inc Recent Development Table 102. Aragen Life Sciences Ltd Company Information Table 103. Aragen Life Sciences Ltd Business Overview Table 104. Aragen Life Sciences Ltd In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 105. Aragen Life Sciences Ltd In Vivo Pharmacology Model Product Portfolio Table 106. Aragen Life Sciences Ltd Recent Development Table 107. Dalriada Company Information Table 108. Dalriada Business Overview Table 109. Dalriada In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 110. Dalriada In Vivo Pharmacology Model Product Portfolio Table 111. Dalriada Recent Development Table 112. Biocytogen Company Information Table 113. Biocytogen Business Overview Table 114. Biocytogen In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 115. Biocytogen In Vivo Pharmacology Model Product Portfolio Table 116. Biocytogen Recent Development Table 117. Charles River Laboratories Company Information Table 118. Charles River Laboratories Business Overview Table 119. Charles River Laboratories In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 120. Charles River Laboratories In Vivo Pharmacology Model Product Portfolio Table 121. Charles River Laboratories Recent Development Table 122. Pharmacelsu Company Information Table 123. Pharmacelsu Business Overview Table 124. Pharmacelsu In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 125. Pharmacelsu In Vivo Pharmacology Model Product Portfolio Table 126. Pharmacelsu Recent Development Table 127. HitGen Inc Company Information Table 128. HitGen Inc Business Overview Table 129. HitGen Inc In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 130. HitGen Inc In Vivo Pharmacology Model Product Portfolio Table 131. HitGen Inc Recent Development Table 132. TCG Lifesciences Company Information Table 133. TCG Lifesciences Business Overview Table 134. TCG Lifesciences In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026) Table 135. TCG Lifesciences In Vivo Pharmacology Model Product Portfolio Table 136. TCG Lifesciences Recent Development Table 137. North America In Vivo Pharmacology Model Market Size by Type (2021-2026) & (US$ Million) Table 138. North America In Vivo Pharmacology Model Market Size by Type (2027-2032) & (US$ Million) Table 139. North America In Vivo Pharmacology Model Market Size by Application (2021-2026) & (US$ Million) Table 140. North America In Vivo Pharmacology Model Market Size by Application (2027-2032) & (US$ Million) Table 141. North America In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 142. North America In Vivo Pharmacology Model Market Size by Country (2021-2026) Table 143. North America In Vivo Pharmacology Model Market Size by Country (2027-2032) Table 144. Europe In Vivo Pharmacology Model Market Size by Type (2021-2026) & (US$ Million) Table 145. Europe In Vivo Pharmacology Model Market Size by Type (2027-2032) & (US$ Million) Table 146. Europe In Vivo Pharmacology Model Market Size by Application (2021-2026) & (US$ Million) Table 147. Europe In Vivo Pharmacology Model Market Size by Application (2027-2032) & (US$ Million) Table 148. Europe In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 149. Europe In Vivo Pharmacology Model Market Size by Country (2021-2026) Table 150. Europe In Vivo Pharmacology Model Market Size by Country (2027-2032) Table 151. China In Vivo Pharmacology Model Market Size by Type (2021-2026) & (US$ Million) Table 152. China In Vivo Pharmacology Model Market Size by Type (2027-2032) & (US$ Million) Table 153. China In Vivo Pharmacology Model Market Size by Application (2021-2026) & (US$ Million) Table 154. China In Vivo Pharmacology Model Market Size by Application (2027-2032) & (US$ Million) Table 155. Asia In Vivo Pharmacology Model Market Size by Type (2021-2026) & (US$ Million) Table 156. Asia In Vivo Pharmacology Model Market Size by Type (2027-2032) & (US$ Million) Table 157. Asia In Vivo Pharmacology Model Market Size by Application (2021-2026) & (US$ Million) Table 158. Asia In Vivo Pharmacology Model Market Size by Application (2027-2032) & (US$ Million) Table 159. Asia In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 160. Asia In Vivo Pharmacology Model Market Size by Country (2021-2026) Table 161. Asia In Vivo Pharmacology Model Market Size by Country (2027-2032) Table 162. South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Type (2021-2026) & (US$ Million) Table 163. South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Type (2027-2032) & (US$ Million) Table 164. South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Application (2021-2026) & (US$ Million) Table 165. South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Application (2027-2032) & (US$ Million) Table 166. South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 167. South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2021-2026) Table 168. South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2027-2032) Table 169. Research Programs/Design for This Report Table 170. Authors List of This Report Table 171. Secondary Sources Table 172. Primary Sources List of Figures Figure 1. In Vivo Pharmacology Model Product Image Figure 2. Global In Vivo Pharmacology Model Market Size Growth Rate by Type, 2021 VS 2025 VS 2032 (US$ Million) Figure 3. Global In Vivo Pharmacology Model Market Share by Type: 2025 VS 2032 Figure 4. Inflammation Animal Models Image Figure 5. Pain and Neuroscience Animal Models Image Figure 6. Diabetes and Metabolic Disorders Animal Models Image Figure 7. Oncology Animal Models Image Figure 8. Others Image Figure 9. Global In Vivo Pharmacology Model Market Size Growth Rate by Application, 2021 VS 2025 VS 2032 (US$ Million) Figure 10. Global In Vivo Pharmacology Model Market Share by Application: 2025 VS 2032 Figure 11. Cardiovascular Diseases Image Figure 12. Neurological Diseases Image Figure 13. Autoimmune Diseases Image Figure 14. Others Image Figure 15. Global In Vivo Pharmacology Model Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 16. Global In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 17. Global In Vivo Pharmacology Model Market Share by Region: 2025 VS 2032 Figure 18. Years Considered Figure 19. Global In Vivo Pharmacology Model Market Share by Players in 2025 Figure 20. Global Top 5 and 10 In Vivo Pharmacology Model Players Market Share by Revenue in 2025 Figure 21. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 22. Global In Vivo Pharmacology Model Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global In Vivo Pharmacology Model Revenue Market Share by Type (2021-2032) Figure 24. Global In Vivo Pharmacology Model Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global In Vivo Pharmacology Model Revenue Market Share by Application (2021-2032) Figure 26. North America In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 27. North America In Vivo Pharmacology Model Market Share by Type (2021-2032) Figure 28. North America In Vivo Pharmacology Model Market Share by Application (2021-2032) Figure 29. North America In Vivo Pharmacology Model Market Share by Country (2021-2032) Figure 30. United States In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 31. Canada In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 32. Mexico In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 33. Europe In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 34. Europe In Vivo Pharmacology Model Market Share by Type (2021-2032) Figure 35. Europe In Vivo Pharmacology Model Market Share by Application (2021-2032) Figure 36. Europe In Vivo Pharmacology Model Market Share by Country (2021-2032) Figure 37. Germany In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 38. France In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 39. U.K. In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 40. Italy In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 41. Russia In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 42. Nordic Countries In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 43. China In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 44. China In Vivo Pharmacology Model Market Share by Type (2021-2032) Figure 45. China In Vivo Pharmacology Model Market Share by Application (2021-2032) Figure 46. Asia In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 47. Asia In Vivo Pharmacology Model Market Share by Type (2021-2032) Figure 48. Asia In Vivo Pharmacology Model Market Share by Application (2021-2032) Figure 49. Asia In Vivo Pharmacology Model Market Share by Country (2021-2032) Figure 50. Japan In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 51. South Korea In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 52. Taiwan In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 53. Southeast Asia In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 54. India In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 55. Australia In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 56. South America, Middle East & Africa In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 57. South America, Middle East & Africa In Vivo Pharmacology Model Market Share by Type (2021-2032) Figure 58. South America, Middle East & Africa In Vivo Pharmacology Model Market Share by Application (2021-2032) Figure 59. South America, Middle East & Africa In Vivo Pharmacology Model Market Share by Country (2021-2032) Figure 60. Brazil In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 61. South Africa In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 62. Saudi Arabia In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 63. Turkey In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 64. Argentina In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 65. UAE In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 66. Egypt In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 67. Chile In Vivo Pharmacology Model Market Size (2021-2032) & (US$ Million) Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • Inflammation Animal Models
  • Pain and Neuroscience Animal Models
  • Diabetes and Metabolic Disorders Animal Models
  • Oncology Animal Models
  • Others
Applications
  • Cardiovascular Diseases
  • Neurological Diseases
  • Autoimmune Diseases
  • Others
Companies covered
  • NuChem Sciences Inc
  • Eurofins Discovery
  • Oncodesign Services
  • Jubilant Biosys
  • Pharmaron
  • Melior Discovery
  • NUVISAN GmbH
  • Porsolt
  • Sygnature Discovery
  • Aurigene Pharmaceutical Services Ltd
  • Reaction Biology
  • Addexbio
  • Paraza Pharma, Inc
  • Aragen Life Sciences Ltd
  • Dalriada
  • Biocytogen
  • Charles River Laboratories
  • Pharmacelsu
  • HitGen Inc
  • TCG Lifesciences

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Market Analysis by Type
  3. 1.2.1 Global In Vivo Pharmacology Model Market Size Growth Rate by Type: 2021 VS 2025 VS 2032
  4. 1.2.2 Inflammation Animal Models
  5. 1.2.3 Pain and Neuroscience Animal Models
  6. 1.2.4 Diabetes and Metabolic Disorders Animal Models
  7. 1.2.5 Oncology Animal Models
  8. 1.2.6 Others
  9. 1.3 Market Analysis by Application
  10. 1.3.1 Global In Vivo Pharmacology Model Market Size Growth Rate by Application: 2021 VS 2025 VS 2032
  11. 1.3.2 Cardiovascular Diseases
  12. 1.3.3 Neurological Diseases
  13. 1.3.4 Autoimmune Diseases
  14. 1.3.5 Others
  15. 1.4 Global Market Growth Prospects
  16. 1.5 Global In Vivo Pharmacology Model Growth Trends by Region
  17. 1.5.1 Global In Vivo Pharmacology Model Market Size by Region: 2021 VS 2025 VS 2032
  18. 1.5.2 In Vivo Pharmacology Model Market Size by Region (2021-2026)
  19. 1.5.3 In Vivo Pharmacology Model Market Size by Region (2027-2032)
  20. 1.6 Assumptions and Limitations
  21. 1.7 Study Goals and Objectives
  22. 1.8 Years Considered
2 Global In Vivo Pharmacology Model Market Dynamics
  1. 2.1 In Vivo Pharmacology Model Industry Trends
  2. 2.2 In Vivo Pharmacology Model Industry Drivers
  3. 2.3 In Vivo Pharmacology Model Industry Opportunities and Challenges
  4. 2.4 In Vivo Pharmacology Model Industry Restraints
3 Competitive Landscape by Company
  1. 3.1 Global In Vivo Pharmacology Model Revenue by Company (2021-2026)
  2. 3.2 Global In Vivo Pharmacology Model Players Revenue Ranking, 2024 VS 2025 VS 2026
  3. 3.3 Global In Vivo Pharmacology Model Key Company Head office and Area Served
  4. 3.4 Global In Vivo Pharmacology Model Company, Product Type & Application
  5. 3.5 Global In Vivo Pharmacology Model Company Establishment Date
  6. 3.6 Market Competitive Analysis
  7. 3.6.1 Global In Vivo Pharmacology Model Market CR5 and HHI
  8. 3.6.2 Global Top 5 and 10 In Vivo Pharmacology Model Players Market Share by Revenue in 2025
  9. 3.6.3 2025 In Vivo Pharmacology Model Tier 1, Tier 2, and Tier 3
4 In Vivo Pharmacology Model Market by Type
  1. 4.1 Global In Vivo Pharmacology Model Market Size by Type (2021 VS 2025 VS 2032)
  2. 4.2 Global In Vivo Pharmacology Model Market Size by Type (2021-2032)
  3. 4.3 Global In Vivo Pharmacology Model Market Size Share by Type (2021-2032)
5 In Vivo Pharmacology Model Market by Application
  1. 5.1 Global In Vivo Pharmacology Model Market Size by Application (2021 VS 2025 VS 2032)
  2. 5.2 Global In Vivo Pharmacology Model Market Size by Application (2021-2032)
  3. 5.3 Global In Vivo Pharmacology Model Market Size Share by Application (2021-2032)
6 Company Profiles
  1. 6.1 NuChem Sciences Inc
  2. 6.1.1 NuChem Sciences Inc Company Information
  3. 6.1.2 NuChem Sciences Inc Business Overview
  4. 6.1.3 NuChem Sciences Inc In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  5. 6.1.4 NuChem Sciences Inc In Vivo Pharmacology Model Product Portfolio
  6. 6.1.5 NuChem Sciences Inc Recent Developments
  7. 6.2 Eurofins Discovery
  8. 6.2.1 Eurofins Discovery Company Information
  9. 6.2.2 Eurofins Discovery Business Overview
  10. 6.2.3 Eurofins Discovery In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  11. 6.2.4 Eurofins Discovery In Vivo Pharmacology Model Product Portfolio
  12. 6.2.5 Eurofins Discovery Recent Developments
  13. 6.3 Oncodesign Services
  14. 6.3.1 Oncodesign Services Company Information
  15. 6.3.2 Oncodesign Services Business Overview
  16. 6.3.3 Oncodesign Services In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  17. 6.3.4 Oncodesign Services In Vivo Pharmacology Model Product Portfolio
  18. 6.3.5 Oncodesign Services Recent Developments
  19. 6.4 Jubilant Biosys
  20. 6.4.1 Jubilant Biosys Company Information
  21. 6.4.2 Jubilant Biosys Business Overview
  22. 6.4.3 Jubilant Biosys In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  23. 6.4.4 Jubilant Biosys In Vivo Pharmacology Model Product Portfolio
  24. 6.4.5 Jubilant Biosys Recent Developments
  25. 6.5 Pharmaron
  26. 6.5.1 Pharmaron Company Information
  27. 6.5.2 Pharmaron Business Overview
  28. 6.5.3 Pharmaron In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  29. 6.5.4 Pharmaron In Vivo Pharmacology Model Product Portfolio
  30. 6.5.5 Pharmaron Recent Developments
  31. 6.6 Melior Discovery
  32. 6.6.1 Melior Discovery Company Information
  33. 6.6.2 Melior Discovery Business Overview
  34. 6.6.3 Melior Discovery In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  35. 6.6.4 Melior Discovery In Vivo Pharmacology Model Product Portfolio
  36. 6.6.5 Melior Discovery Recent Developments
  37. 6.7 NUVISAN GmbH
  38. 6.7.1 NUVISAN GmbH Company Information
  39. 6.7.2 NUVISAN GmbH Business Overview
  40. 6.7.3 NUVISAN GmbH In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  41. 6.7.4 NUVISAN GmbH In Vivo Pharmacology Model Product Portfolio
  42. 6.7.5 NUVISAN GmbH Recent Developments
  43. 6.8 Porsolt
  44. 6.8.1 Porsolt Company Information
  45. 6.8.2 Porsolt Business Overview
  46. 6.8.3 Porsolt In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  47. 6.8.4 Porsolt In Vivo Pharmacology Model Product Portfolio
  48. 6.8.5 Porsolt Recent Developments
  49. 6.9 Sygnature Discovery
  50. 6.9.1 Sygnature Discovery Company Information
  51. 6.9.2 Sygnature Discovery Business Overview
  52. 6.9.3 Sygnature Discovery In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  53. 6.9.4 Sygnature Discovery In Vivo Pharmacology Model Product Portfolio
  54. 6.9.5 Sygnature Discovery Recent Developments
  55. 6.10 Aurigene Pharmaceutical Services Ltd
  56. 6.10.1 Aurigene Pharmaceutical Services Ltd Company Information
  57. 6.10.2 Aurigene Pharmaceutical Services Ltd Business Overview
  58. 6.10.3 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  59. 6.10.4 Aurigene Pharmaceutical Services Ltd In Vivo Pharmacology Model Product Portfolio
  60. 6.10.5 Aurigene Pharmaceutical Services Ltd Recent Developments
  61. 6.11 Reaction Biology
  62. 6.11.1 Reaction Biology Company Information
  63. 6.11.2 Reaction Biology Business Overview
  64. 6.11.3 Reaction Biology In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  65. 6.11.4 Reaction Biology In Vivo Pharmacology Model Product Portfolio
  66. 6.11.5 Reaction Biology Recent Developments
  67. 6.12 Addexbio
  68. 6.12.1 Addexbio Company Information
  69. 6.12.2 Addexbio Business Overview
  70. 6.12.3 Addexbio In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  71. 6.12.4 Addexbio In Vivo Pharmacology Model Product Portfolio
  72. 6.12.5 Addexbio Recent Developments
  73. 6.13 Paraza Pharma, Inc
  74. 6.13.1 Paraza Pharma, Inc Company Information
  75. 6.13.2 Paraza Pharma, Inc Business Overview
  76. 6.13.3 Paraza Pharma, Inc In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  77. 6.13.4 Paraza Pharma, Inc In Vivo Pharmacology Model Product Portfolio
  78. 6.13.5 Paraza Pharma, Inc Recent Developments
  79. 6.14 Aragen Life Sciences Ltd
  80. 6.14.1 Aragen Life Sciences Ltd Company Information
  81. 6.14.2 Aragen Life Sciences Ltd Business Overview
  82. 6.14.3 Aragen Life Sciences Ltd In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  83. 6.14.4 Aragen Life Sciences Ltd In Vivo Pharmacology Model Product Portfolio
  84. 6.14.5 Aragen Life Sciences Ltd Recent Developments
  85. 6.15 Dalriada
  86. 6.15.1 Dalriada Company Information
  87. 6.15.2 Dalriada Business Overview
  88. 6.15.3 Dalriada In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  89. 6.15.4 Dalriada In Vivo Pharmacology Model Product Portfolio
  90. 6.15.5 Dalriada Recent Developments
  91. 6.16 Biocytogen
  92. 6.16.1 Biocytogen Company Information
  93. 6.16.2 Biocytogen Business Overview
  94. 6.16.3 Biocytogen In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  95. 6.16.4 Biocytogen In Vivo Pharmacology Model Product Portfolio
  96. 6.16.5 Biocytogen Recent Developments
  97. 6.17 Charles River Laboratories
  98. 6.17.1 Charles River Laboratories Company Information
  99. 6.17.2 Charles River Laboratories Business Overview
  100. 6.17.3 Charles River Laboratories In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  101. 6.17.4 Charles River Laboratories In Vivo Pharmacology Model Product Portfolio
  102. 6.17.5 Charles River Laboratories Recent Developments
  103. 6.18 Pharmacelsu
  104. 6.18.1 Pharmacelsu Company Information
  105. 6.18.2 Pharmacelsu Business Overview
  106. 6.18.3 Pharmacelsu In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  107. 6.18.4 Pharmacelsu In Vivo Pharmacology Model Product Portfolio
  108. 6.18.5 Pharmacelsu Recent Developments
  109. 6.19 HitGen Inc
  110. 6.19.1 HitGen Inc Company Information
  111. 6.19.2 HitGen Inc Business Overview
  112. 6.19.3 HitGen Inc In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  113. 6.19.4 HitGen Inc In Vivo Pharmacology Model Product Portfolio
  114. 6.19.5 HitGen Inc Recent Developments
  115. 6.20 TCG Lifesciences
  116. 6.20.1 TCG Lifesciences Company Information
  117. 6.20.2 TCG Lifesciences Business Overview
  118. 6.20.3 TCG Lifesciences In Vivo Pharmacology Model Revenue and Gross Margin (US$ Million) & (2021-2026)
  119. 6.20.4 TCG Lifesciences In Vivo Pharmacology Model Product Portfolio
  120. 6.20.5 TCG Lifesciences Recent Developments
7 North America
  1. 7.1 North America In Vivo Pharmacology Model Market Size (2021-2032)
  2. 7.2 North America In Vivo Pharmacology Model Market Size by Type
  3. 7.2.1 North America In Vivo Pharmacology Model Market Size by Type (2021-2026)
  4. 7.2.2 North America In Vivo Pharmacology Model Market Size by Type (2027-2032)
  5. 7.2.3 North America In Vivo Pharmacology Model Market Share by Type (2021-2032)
  6. 7.3 North America In Vivo Pharmacology Model Market Size by Application
  7. 7.3.1 North America In Vivo Pharmacology Model Market Size by Application (2021-2026)
  8. 7.3.2 North America In Vivo Pharmacology Model Market Size by Application (2027-2032)
  9. 7.3.3 North America In Vivo Pharmacology Model Market Share by Application (2021-2032)
  10. 7.4 North America In Vivo Pharmacology Model Market Size by Country
  11. 7.4.1 North America In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032)
  12. 7.4.2 North America In Vivo Pharmacology Model Market Size by Country (2021-2026)
  13. 7.4.3 North America In Vivo Pharmacology Model Market Size by Country (2027-2032)
  14. 7.4.4 North America In Vivo Pharmacology Model Market Share by Country (2021-2032)
  15. 7.4.5 United States
  16. 7.4.6 Canada
  17. 7.4.7 Mexico
8 Europe
  1. 8.1 Europe In Vivo Pharmacology Model Market Size (2021-2032)
  2. 8.2 Europe In Vivo Pharmacology Model Market Size by Type
  3. 8.2.1 Europe In Vivo Pharmacology Model Market Size by Type (2021-2026)
  4. 8.2.2 Europe In Vivo Pharmacology Model Market Size by Type (2027-2032)
  5. 8.2.3 Europe In Vivo Pharmacology Model Market Share by Type (2021-2032)
  6. 8.3 Europe In Vivo Pharmacology Model Market Size by Application
  7. 8.3.1 Europe In Vivo Pharmacology Model Market Size by Application (2021-2026)
  8. 8.3.2 Europe In Vivo Pharmacology Model Market Size by Application (2027-2032)
  9. 8.3.3 Europe In Vivo Pharmacology Model Market Share by Application (2021-2032)
  10. 8.4 Europe In Vivo Pharmacology Model Market Size by Country
  11. 8.4.1 Europe In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032)
  12. 8.4.2 Europe In Vivo Pharmacology Model Market Size by Country (2021-2026)
  13. 8.4.3 Europe In Vivo Pharmacology Model Market Size by Country (2027-2032)
  14. 8.4.4 Europe In Vivo Pharmacology Model Market Share by Country (2021-2032)
  15. 8.4.5 Germany
  16. 8.4.6 France
  17. 8.4.7 U.K.
  18. 8.4.8 Italy
  19. 8.4.9 Russia
  20. 8.4.10 Nordic Countries
9 China
  1. 9.1 China In Vivo Pharmacology Model Market Size (2021-2032)
  2. 9.2 China In Vivo Pharmacology Model Market Size by Type
  3. 9.2.1 China In Vivo Pharmacology Model Market Size by Type (2021-2026)
  4. 9.2.2 China In Vivo Pharmacology Model Market Size by Type (2027-2032)
  5. 9.2.3 China In Vivo Pharmacology Model Market Share by Type (2021-2032)
  6. 9.3 China In Vivo Pharmacology Model Market Size by Application
  7. 9.3.1 China In Vivo Pharmacology Model Market Size by Application (2021-2026)
  8. 9.3.2 China In Vivo Pharmacology Model Market Size by Application (2027-2032)
  9. 9.3.3 China In Vivo Pharmacology Model Market Share by Application (2021-2032)
10 Asia (Excluding China)
  1. 10.1 Asia In Vivo Pharmacology Model Market Size (2021-2032)
  2. 10.2 Asia In Vivo Pharmacology Model Market Size by Type
  3. 10.2.1 Asia In Vivo Pharmacology Model Market Size by Type (2021-2026)
  4. 10.2.2 Asia In Vivo Pharmacology Model Market Size by Type (2027-2032)
  5. 10.2.3 Asia In Vivo Pharmacology Model Market Share by Type (2021-2032)
  6. 10.3 Asia In Vivo Pharmacology Model Market Size by Application
  7. 10.3.1 Asia In Vivo Pharmacology Model Market Size by Application (2021-2026)
  8. 10.3.2 Asia In Vivo Pharmacology Model Market Size by Application (2027-2032)
  9. 10.3.3 Asia In Vivo Pharmacology Model Market Share by Application (2021-2032)
  10. 10.4 Asia In Vivo Pharmacology Model Market Size by Country
  11. 10.4.1 Asia In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032)
  12. 10.4.2 Asia In Vivo Pharmacology Model Market Size by Country (2021-2026)
  13. 10.4.3 Asia In Vivo Pharmacology Model Market Size by Country (2027-2032)
  14. 10.4.4 Asia In Vivo Pharmacology Model Market Share by Country (2021-2032)
  15. 10.4.5 Japan
  16. 10.4.6 South Korea
  17. 10.4.7 Taiwan
  18. 10.4.8 Southeast Asia
  19. 10.4.9 India
  20. 10.4.10 Australia
11 South America, Middle East & Africa
  1. 11.1 South America, Middle East & Africa In Vivo Pharmacology Model Market Size (2021-2032)
  2. 11.2 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Type
  3. 11.2.1 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Type (2021-2026)
  4. 11.2.2 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Type (2027-2032)
  5. 11.2.3 South America, Middle East & Africa In Vivo Pharmacology Model Market Share by Type (2021-2032)
  6. 11.3 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Application
  7. 11.3.1 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Application (2021-2026)
  8. 11.3.2 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Application (2027-2032)
  9. 11.3.3 South America, Middle East & Africa In Vivo Pharmacology Model Market Share by Application (2021-2032)
  10. 11.4 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Country
  11. 11.4.1 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2021 VS 2025 VS 2032)
  12. 11.4.2 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2021-2026)
  13. 11.4.3 South America, Middle East & Africa In Vivo Pharmacology Model Market Size by Country (2027-2032)
  14. 11.4.4 South America, Middle East & Africa In Vivo Pharmacology Model Market Share by Country (2021-2032)
  15. 11.4.5 Brazil
  16. 11.4.6 South Africa
  17. 11.4.7 Saudi Arabia
  18. 11.4.8 Turkey
  19. 11.4.9 Argentina
  20. 11.4.9 UAE
  21. 11.4.9 Egypt
  22. 11.4.9 Chile
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources
    8. 13.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst